Rezultati pretraživanja
  1. 7. sij

    Announces 1st Patient Enrollment in Phase 1b/2 study of for Acute Treatment of Agitation Associated with Dementia.

  2. BioXcel Therapeutics Announces Clearance of IND Application for for the Treatment of Withdrawal Symptoms.

  3. 3. pro 2019.
  4. 8. sij 2019.

    The has granted Fast Track designation to , an investigational treatment for .

  5. 10. lis 2019.

    supports & challenges people face with . Phase 3 results expected 1H 2020 for those suffering from .

  6. 21. kol 2019.
  7. 20. tra 2018.

    BioXcel Therapeutics to Ring the Stock Market Opening Bell on April 20, 2018. Join us live:

  8. 27. sij
  9. 3. velj
  10. 30. lis 2019.

    Our CEO and founder Dr. Vimal Mehta shared 's exciting news with . is developing (such as watch) to help combat .

  11. 10. lis 2019.
  12. hopes to use wearable digital devices like the to predict whether patients with ’s are becoming agitated, so that the company’s drug can be administered to prevent the episode from escalating.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.